Frank Konrad F, Bölck Birgit, Erdmann Erland, Schwinger Robert H G
Clinic III of Internal Medicine, Laboratory of Muscle Research and Molecular Cardiology, University of Cologne, Cologne, Germany.
Cardiovasc Res. 2003 Jan;57(1):20-7. doi: 10.1016/s0008-6363(02)00694-6.
The cardiac SR Ca(2+)-ATPase (SERCA2a) regulates intracellular Ca(2+)-handling and thus, plays a crucial role in initiating cardiac contraction and relaxation. SERCA2a may be modulated through its accessory phosphoprotein phospholamban or by direct phosphorylation through Ca(2+)/calmodulin dependent protein kinase II (CaMK II). As an inhibitory component phospholamban, in its dephosphorylated form, inhibits the Ca(2+)-dependent SERCA2a function, while protein kinase A dependent phosphorylation of the phospho-residues serine-16 or Ca(2+)/calmodulin-dependent phosphorylation of threonine-17 relieves this inhibition. Recent evidence suggests that direct phosphorylation at residue serine-38 in SERCA2a activates enzyme function and enhances Ca(2+)-reuptake into the sarcoplasmic reticulum (SR). These effects that are mediated through phosphorylation result in an overall increased SR Ca(2+)-load and enhanced contractility. In human heart failure patients, as well as animal models with induced heart failure, these modulations are altered and may result in an attenuated SR Ca(2+)-storage and modulated contractility. It is also believed that abnormalities in Ca(2+)-cycling are responsible for blunting the frequency potentiation of contractile force in the failing human heart. Advanced gene expression and modulatory approaches have focused on enhancing SERCA2a function via overexpressing SERCA2a under physiological and pathophysiological conditions to restore cardiac function, cardiac energetics and survival rate.
心脏肌浆网Ca(2+)-ATP酶(SERCA2a)调节细胞内Ca(2+)的处理,因此在启动心脏收缩和舒张中起关键作用。SERCA2a可通过其辅助磷蛋白受磷蛋白调节,或通过Ca(2+)/钙调蛋白依赖性蛋白激酶II(CaMK II)直接磷酸化进行调节。作为一种抑制成分,受磷蛋白以去磷酸化形式抑制Ca(2+)依赖性SERCA2a的功能,而蛋白激酶A依赖性的丝氨酸-16磷酸化残基或苏氨酸-17的Ca(2+)/钙调蛋白依赖性磷酸化可解除这种抑制。最近的证据表明,SERCA2a中丝氨酸-38残基的直接磷酸化可激活酶的功能,并增强Ca(2+)重新摄取到肌浆网(SR)中。这些通过磷酸化介导的效应导致SR Ca(2+)负荷总体增加和收缩性增强。在人类心力衰竭患者以及诱导性心力衰竭动物模型中,这些调节发生改变,可能导致SR Ca(2+)储存减弱和收缩性调节。也有人认为,Ca(2+)循环异常是导致衰竭人类心脏收缩力频率增强减弱的原因。先进的基因表达和调节方法集中在通过在生理和病理生理条件下过表达SERCA2a来增强其功能,以恢复心脏功能、心脏能量代谢和存活率。